Chemistry:Cyamemazine: Difference between revisions
Pchauhan2001 (talk | contribs) (add) |
(No difference)
|
Latest revision as of 10:31, 8 February 2024
![]() | |
Clinical data | |
---|---|
Trade names | Tercian |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Oral, IM, IV |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 10-70% |
Metabolism | Hepatic |
Elimination half-life | 10 hours |
Excretion | Urine |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C19H21N3S |
Molar mass | 323.46 g·mol−1 |
3D model (JSmol) | |
| |
| |
![]() ![]() |
Cyamemazine (Tercian), also known as cyamepromazine, is a typical antipsychotic drug of the phenothiazine class which was introduced by Theraplix in France in 1972 and later in Portugal as well.[1][2][3][4]
Medical use
It is used for the treatment of schizophrenia and, especially, for psychosis-associated anxiety, due to its unique anxiolytic efficacy.[5][6]
It is also used to reduce anxiety associated with benzodiazepine withdrawal syndrome and anxiety in depression with suicidal tendency.[7]
Side effects
Here are some of the most common side effects and related incidence:[8]
- Sedation (20%)
- Vertigo (7.9%)
- Constipation (4%)
- Dyskinesia (4.4%)
- Dryness of mouth (5.9%)
- Hypotension (7.4%)
- Tachycardia (3.2%)
Mechanism
Cyamemazine differs from other phenothiazine neuroleptics in that aside from the usual profile of dopamine, α1-adrenergic, H1, and mACh receptor antagonism,[9] it additionally produces potent blockade of several serotonin receptors, including 5-HT2A, 5-HT2C, and 5-HT7.[9][10][11][12] These actions have been implicated in cyamemazine's anxiolytic effects (5-HT2C) and lack of extrapyramidal side effects (5-HT2A),[9][10] and despite being classified as a typical antipsychotic, it actually behaves like an atypical antipsychotic.[13]
Site | Ki (nM) | Species | Ref |
---|---|---|---|
H1 | 9.3 | Guinea pig | [14] |
H2 | 351 | Guinea pig | [14] |
H3 | >10,000 | Rat | [14] |
M1 | 13 | Human | [14] |
M2 | 42 | Human | [14] |
M3 | 32 | Human | [14] |
M4 | 12 | Human | [14] |
M5 | 35 | Human | [14] |
5-HT1A | 517 | Human | [14] |
5-HT2A | 1.5 | Human | [14] |
5-HT2C | 12 | Human | [14] |
5-HT3 | 2,943 | Human | [14] |
5-HT7 | 22 | Human | [14] |
D1 | 3.8 | Human | [14] |
D2 | 5.8 | Human | [14] |
D3 | 2.5 | Human | [14] |
D4 | 5.3 | Human | [14] |
α1 | 2.3 | Rat | [14] |
α2 | 1320 | Rat | [14] |
GABAA | >10,000 | Rat | [14] |
GABAB | >10,000 | Rat | [14] |
Values are Ki (nM). The smaller the value,
the more strongly the drug binds to the site. |
Synthesis
2-Cyanophenothiazine [38642-74-9] (1) 3-Chloro-2-methylpropyl(dimethyl)amine [23349-86-2] (2)
References
- ↑ Index Nominum, International Drug. Taylor & Francis. 2000. ISBN 978-3-88763-075-1. https://books.google.com/books?id=5GpcTQD_L2oC&q=cyamemazine%20tercian&pg=PA280.
- ↑ Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. 1996. p. 534. ISBN 0-412-46630-9. https://books.google.com/books?id=DeX7jgInYFMC&pg=RA1-PA534.
- ↑ Pharmaceutical manufacturing ... - Google Books. Noyes Publications. January 1988. ISBN 9780815511441. https://books.google.com/books?id=X2EyLsG4bcUC&q=cyamemazine%20introduced&pg=PA397.
- ↑ "[Prescribing patterns of antipsychotics in 13 French psychiatric hospitals"] (in fr). L'Encephale 35 (2): 129–138. April 2009. doi:10.1016/j.encep.2008.03.007. PMID 19393381. http://www.masson.fr/masson/S0013-7006(08)00103-6.
- ↑ "Cyamemazine". Stahl's Essential Psychopharmacology. Cambridge University Press. http://stahlonline.cambridge.org/prescribers_drug.jsf?page=0521683505c20_p115-120.html.therapeutics&name=Cyamemazine.
- ↑ "Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice". Behavioural Brain Research 124 (1): 87–95. September 2001. doi:10.1016/S0166-4328(01)00238-8. PMID 11423169.
- ↑ "Potential role of cortical 5-HT(2A) receptors in the anxiolytic action of cyamemazine in benzodiazepine withdrawal". Psychiatry Research (Elsevier BV) 198 (2): 307–312. July 2012. doi:10.1016/j.psychres.2012.01.009. PMID 22421069.
- ↑ "Preclinical and clinical pharmacology of cyamemazine: anxiolytic effects and prevention of alcohol and benzodiazepine withdrawal syndrome". CNS Drug Reviews (Wiley) 10 (3): 219–229. 2006-06-07. doi:10.1111/j.1527-3458.2004.tb00023.x. PMID 15492772.
- ↑ 9.0 9.1 9.2 "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology 65 (3): 435–440. February 2003. doi:10.1016/S0006-2952(02)01515-0. PMID 12527336.
- ↑ 10.0 10.1 "5-HT3- and 5-HT2C-antagonist properties of cyamemazine: significance for its clinical anxiolytic activity". Psychopharmacology 147 (4): 412–417. January 2000. doi:10.1007/s002130050010. PMID 10672635. http://link.springer.de/link/service/journals/00213/bibs/0147004/01470412.htm. Retrieved 2010-02-11.
- ↑ "5-HT2A receptor antagonist properties of cyamemazine in rat and guinea pig smooth muscle". European Journal of Pharmacology 454 (2–3): 235–239. November 2002. doi:10.1016/S0014-2999(02)02489-5. PMID 12421652.
- ↑ "Affinity of cyamemazine metabolites for serotonin, histamine and dopamine receptor subtypes". European Journal of Pharmacology 578 (2–3): 142–147. January 2008. doi:10.1016/j.ejphar.2007.09.025. PMID 17936750.
- ↑ "Reduction of extracellular dopamine and metabolite concentrations in rat striatum by low doses of acute cyamemazine". Naunyn-Schmiedeberg's Archives of Pharmacology 367 (2): 134–139. February 2003. doi:10.1007/s00210-002-0665-4. PMID 12595954.
- ↑ 14.00 14.01 14.02 14.03 14.04 14.05 14.06 14.07 14.08 14.09 14.10 14.11 14.12 14.13 14.14 14.15 14.16 14.17 14.18 14.19 14.20 "Affinity of cyamemazine, an anxiolytic antipsychotic drug, for human recombinant dopamine vs. serotonin receptor subtypes". Biochemical Pharmacology 65 (3): 435–440. February 2003. doi:10.1016/s0006-2952(02)01515-0. PMID 12527336.
- ↑ "Synthesis of Phenothiazines. VI. Certain 2-Substituted Phenothiazines and Their 10-Aminoalkyl Derivatives". The Journal of Organic Chemistry 26 (4): 1138–1143. 1961. doi:10.1021/jo01063a040.
- ↑ Jacob RM, Georges RJ gdate = 1959, US patent 2877224, assigned to Rhone Poulenc Sa
![]() | Original source: https://en.wikipedia.org/wiki/Cyamemazine.
Read more |